ArticleFrontiers in microbiology2019
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Resistance of gram-negative and gram-positive pathogens to omadacycline: a systematic review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Global trends and research profile of antibiotic heteroresistance: a bibliometric and visual analysis.Frontiers in microbiology · 2026Pooled it
- Global prevalence of macrolide-resistantFrontiers in microbiology · 2025Pooled it
- Dual population-level processes contribute to polyclonal ceftiofur heteroresistance in swine-derivedVirulence · 2026Article
- Eravacycline and omadacycline Rescue multidrug-resistant Elizabethkingia anophelis: Triple-Model evaluation across in Vitro, Galleria mellonella, and murine bacteremia systems.Journal of advanced research · 2026Article
- Addendum: ESKAPE pathogens rapidly develop resistance against antibiotics in development in vitro.Nature microbiology · 2026Article
- Mechanisms ofInternational journal of molecular sciences · 2025Article
- A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections.Military medicine · 2024Review
- Detection and characterization of eravacycline heteroresistance in clinical bacterial isolates.Frontiers in microbiology · 2024Article
- Staph wars: the antibiotic pipeline strikes back.Microbiology (Reading, England) · 2023Review
- Clemastine Inhibits the Biofilm and Hemolytic of Staphylococcus aureus through the GdpP Protein.Microbiology spectrum · 2022Article
- Omadacycline Efficacy againstComputational intelligence and neuroscience · 2022Article
- Article
- Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline.Pharmacotherapy · 2021Review
- Article
- Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study.BMC microbiology · 2020Article
- Amidochelocardin Overcomes Resistance Mechanisms Exerted on Tetracyclines and Natural Chelocardin.Antibiotics (Basel, Switzerland) · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omadacycline (Omad), a new tetracycline (Tet)-class broad-spectrum aminomethylcycline, has been reported to exhibit excellent potency against Gram-positive bacteria, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.